Recorded fact · drug.label_indication
drug.label_indication for acalabrutinib|mantle-cell-lymphoma
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 87f9f6fb resolves to.
The record
| Fact id | 87f9f6fb990eb16283d3911c |
|---|---|
| Entity | drug: acalabrutinib|mantle-cell-lymphoma |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260219 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 7108818d8995dd24bdede64543c1aad1d4cb42c7b64fd83b81954e6bdf77f6f5.
The value
{
"ingredient": "ACALABRUTINIB",
"conditionId": "mantle-cell-lymphoma",
"conditionName": "Mantle Cell Lymphoma",
"matchedAlias": "mantle cell lymphoma",
"context": "indication",
"brand": "CALQUENCE",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "dd4835ef-e1bc-4997-a399-1ffa2556fbfe",
"labelEffectiveTime": "20260219",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: a572a913ff20600f01d6b205ccfa3073c074ee81949aadeca4dc8896b28fc7f2.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.